Drug Type Small molecule drug |
Synonyms SY5007 |
Target |
Mechanism RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 25 Oct 2023 | |
RET fusion-positive Non-Small Cell Lung Cancer | Phase 3 | CN | 20 Jun 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 23 Apr 2021 | |
Thyroid Cancer, Medullary | Phase 2 | CN | 23 Apr 2021 |
Phase 2 | Advanced Malignant Solid Neoplasm | Non-Small Cell Lung Cancer | Thyroid Cancer, Medullary RET-fusion positive | 105 | fxzquwvohz(aerswvhyno) = ievnfeykxg xvbywasqex (izkzmuefdh, 67.9 - 84.8) View more | Positive | 24 May 2024 | ||
NCT05278364 (ASCO2023) Manual | Phase 1 | RET fusion-positive Solid Tumors RET positive | 60 | jmbgjuweym(rhhimnrvyf) = wjrubtazlr wzxzmpymyy (poqnxrxpuo, 72.7 - 97.8) View more | Positive | 31 May 2023 | |
(NSCLC+MTC) | jmbgjuweym(rhhimnrvyf) = auoxxquhmq wzxzmpymyy (poqnxrxpuo, 73.0 - 99.0) View more |